Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease

Gyuri Kim1,2, Kwang Joon Kim1, Yumie Rhee1, Sung-Kil Lim1*

1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea,
2 Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Abstract

Background
Metabolic bone disorders frequently occur in patients with chronic liver disease; however, the association between liver fibrosis and bone mineral density in patients with non-alcoholic fatty liver disease (NAFLD) is unclear.

Methods
This is a cross-sectional analysis of 231 asymptomatic subjects (160 women, 61.6 years old) from a university hospital setting, between February 2012 and December 2014. Bone mineral density (BMD) was measured at the lumbar spine, femur neck, and total hip using dual-energy X-ray absorptiometry (DXA). Liver fibrosis and steatosis were assessed using transient elastography.

Results
Among a total of 231 individuals, 129 subjects (55.8%) had NAFLD. BMDs at lumbar spine, femur neck, and total hip were significantly lower in patients having NAFLD with significant fibrosis, compared with patients having NAFLD without significant fibrosis (Ps<0.005). In patients with NAFLD, significant liver fibrosis revealed marked negative correlations with BMD at the lumber spine (r = –0.19, P = 0.032), femur neck (r = –0.19, P = 0.034), and total hip (r = –0.21, P = 0.016). A multivariate linear regression analysis revealed that significant liver fibrosis was independently correlated with low BMD at the femur neck (β = –0.18, P = 0.039) and total hip (β = –0.21, P = 0.005) after adjustment for age, sex, BMI, fasting plasma glucose, alanine aminotransferase, high-density lipoprotein cholesterol, and liver steatosis among patients with NAFLD. Using multivariable logistic regression, significant liver fibrosis was independently associated with overall osteopenia and osteoporosis in subjects having NAFLD (OR = 4.10, 95% CI = 1.02–16.45).
Conclusion
The presence of significant liver fibrosis assessed via TE was independently associated with low BMD in NAFLD subjects.

Introduction
Non-alcoholic fatty liver disease (NAFLD), one of the most common chronic metabolic liver disorders, is a major public health problem strongly correlated with growing prevalence of obesity or diabetes [1]. NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), representing progressive inflammation, which can progress to liver cirrhosis or hepatocellular carcinoma. Oxidative stress, pro-inflammatory cytokines, and lipotoxicity, in conjunction with various inflammatory reactions and fibrosis, have been found to be related with an increased risk of NASH and fibrosis progression [2]. Recently, liver fibrosis diagnosed based on liver biopsy rather than NAFLD activity score (NAS), a histological scoring system including features of steatosis, lobular inflammation, and hepatocellular ballooning but not fibrosis, was suggested to be the main crucial prognostic factor for overall and liver-related mortality in subjects with NAFLD [3,4].

Metabolic bone disease in patients with liver disease, known as hepatic osteodystrophy, is characterized by poor bone mineralization and loss of bone mass and quality, and its prevalence has also rapidly increased [5]. Several studies reported a degree of association between NAFLD and low bone mineral density (BMD), showing a higher risk of osteoporosis in postmenopausal women with NAFLD [6]. The association between NAFLD and osteopenia remains controversial. Furthermore, few studies have investigated whether NAFLD with liver fibrosis and low BMD are distinctively related to each other and whether significant liver fibrosis is an independent determinant of low BMD.

Osteoclasts and osteoblasts execute bone remodeling by resorbing and forming bone respectively, and physiological bone remodeling is tightly regulated by osteocytes. Multiple mediators, including oncofetal fibronectin, insulin-like growth factor-1 (IGF-1), the receptor activator of the nuclear factor kappa B ligand/ostearthropetegerin (RANKL/OPG) pathway, and several inflammatory cytokines (e.g. tumor necrosis factor [TNF]-α, interleukin-6 [IL-6], and IL-17), are commonly involved in the process of bone loss by affecting the above cells and inducing an imbalance between bone formation and bone resorption in patients with liver disease [7–9]. In line with this, we hypothesized that progressive liver fibrosis in NAFLD indicating severe inflammatory status is associated with low BMD.

Chronic liver disease including NAFLD or liver cirrhosis assessed via abdominal ultrasonography or liver biopsy was reported to be associated with low bone mass [10–12]. However, abdominal ultrasonography often lacks the sensitivity required to identify early steatosis, and liver biopsy is an invasive procedure; performing liver biopsies on all at-risk individuals is not feasible in clinical practice [13]. To overcome this limitation, liver transient elastography (TE, Fibroscan) has been widely used as a non-invasive, easy, and rapid method for quantification and evaluation of liver fibrosis or steatosis [14,15]. Recently, several studies reported that liver stiffness measurement by using TE was a clinically useful noninvasive alternative to liver biopsy, providing a numerical value and well reflecting liver fibrosis [16,17]. In addition, simultaneous evaluation of hepatic steatosis by using the controlled attenuation parameter (CAP) based on TE has proven to be efficient in differentiating steatosis grades [18]. Therefore, in this present study, we identified patients with NAFLD and measured liver stiffness by using
non-invasive TE in order to investigate the association between liver fibrosis and BMD in individuals with NAFLD.

**Materials and methods**

**The study population**

This study retrospectively included 440 asymptomatic individuals who underwent evaluation via both dual-energy X-ray absorptiometry (DXA) and TE for a health check-up at the university-affiliated Severance Hospital, Seoul, Republic of Korea, between February 2012 and December 2014. As shown in Fig 1, exclusion criteria for this study were as follows: women aged ≤ 50 years (n = 57) to exclude pre-menopausal women, any etiological markers for chronic liver disease including positive serologic markers for hepatitis B virus (n = 53) and hepatitis C virus (n = 17), autoimmune hepatitis (n = 5), history of alcohol consumption > 210 g/week for men and 140 g/week for women (n = 7), presence of primary biliary cirrhosis.

---

**Fig 1. Study subject disposition.**

https://doi.org/10.1371/journal.pone.0182202.g001
(n = 3), presence of right-sided heart failure (n = 4), prior history of malignancy (n = 9), invalid liver stiffness value (n = 12), and sequential data from identical subjects (n = 42). Ultimately, a total of 231 individuals were analyzed in this study. Informed consent for this study was not required because the database was only accessed for purpose of analysis without personal information. The protocol of this study was approved by the Institutional Review Board (IRB No. 4-2015-0285) of Severance Hospital.

Clinical and laboratory variables

Body mass index (BMI) was defined as weight divided by the square of the height (kg/m$^2$). Blood samples were obtained after an 8-hour fast. Routine serum chemistry determinations including plasma glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), calcium, and albumin were performed using standard automated laboratory techniques; 25-hydroxyvitamin D was assayed using D3-radioimmunoassay-coated tubes (Biosource, Nivelles, Belgium). Glycated hemoglobin (HbA$_{1c}$) was measured as previously described [19]. Plasma total cholesterol, triglycerides (TG), and high-density lipoprotein (HDL) cholesterol levels were measured using a Hitachi 7600 Auto Analyzer (Hitachi Instruments Service, Tokyo, Japan). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation (LDL cholesterol [mg/dL] = total cholesterol [mg/dL]–HDL cholesterol [mg/dL] – TG [mg/dL] / 5) [20].

Measurement of bone mineral density via DXA

Areal BMD was measured for the lumbar spine from L1 to L4, the femoral neck, and the total hip in all subjects using DXA (Hologic Delphi A version 12.6, Hologic, Waltham, MA, USA). Results are expressed as BMD (g/cm$^2$) and T-scores. T-scores were calculated using reference values from the National Health and Nutrition Examination Survey (NHANES) III [21]. Osteoporosis was defined as a T-score of less than or equal to –2.5 at least one out of the three skeletal sites (lumbar spine, femur neck, or total hip) while osteopenia was between –1.0 and –2.5 at any one of these three sites, according to World Health Organization criteria [22].

Measurement of liver stiffness and controlled attenuation parameter using TE

The measurement of liver stiffness (LS), CAP, and variability using TE was assessed as described previously [23–25]. Transient elastography (fibroscan) was performed by one experienced technician (more than 10,000 examinations), who was blind to patients’ clinical data [25]. The results are described as decibels per meter (dB/m) and kilopascals (kPa) for CAP and LS, respectively. The interquartile range (IQR) was assessed as an index of the intrinsic variability of LS values corresponding to the interval of LS values containing 50% of the valid measurements between the 25th and 75th percentiles. Only cases with at least 10 validated acquisitions, a success rate of at least 60%, and a ratio of the IQR of LS to median values (IQR/M$_{LS}$) less than 0.3 were considered reliable [26]. The CAP was determined only when LS measurement was reliable for the simultaneous signals at the same volume of liver parenchyma, and the final CAP value was the median of individual CAP values using the same valid measurements [27]. In this study, a cut-off point of CAP $\geq$250 dB/m was defined as nonalcoholic fatty liver disease (NAFLD), and a cut-off point of LS $>7.0$ kPa was defined as significant liver fibrosis assessed via TE, based on previous studies [27,28].
Statistical analyses

All continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as proportions. Differences were analyzed using independent Student’s t-tests or Mann-Whitney U-tests for continuous variables and chi-square tests or Fisher’s exact tests for categorical variables. Pearson’s correlation analysis was performed to examine the relationships between BMD and metabolic variables. A multivariate linear regression analysis was performed to determine the independent relationships of the studied variables, and standardized β was represented as the coefficient β. The odds ratios (ORs) and 95% confidence intervals (CIs) for significant liver fibrosis associated with overall osteopenia and osteoporosis were calculated using multivariate logistic regression analysis. In multivariate analysis, model 1 was a crude form and model 2 adjusted for age, sex, and BMI. In model 3, we adjusted for model 2 covariates in addition to fasting plasma glucose. Model 4 adjusted for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP. A P value of <0.05 was considered to be statistically significant. Statistical analyses were performed using PASW Statistics software, version 20.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results

Baseline characteristics of the study population

The baseline clinical and laboratory characteristics of the total study population are shown in Table 1. For all subjects (n = 231), the mean age was 61.8 ± 8.4 years, and 160 (69.3%) were women. The mean BMI was 24.5 ± 3.3 kg/m². A total 18.6% of patients had a history of diabetes (n = 43), and 15.4% had osteoporosis (n = 36). Of these 231 subjects, 129 (55.8%) had NAFLD. The subjects with NAFLD had significantly increased BMI, higher levels of HbA1c, fasting plasma glucose, ALT, albumin, TG, lower levels of HDL, and a higher proportion of significant liver fibrosis relative to subjects without NAFLD. In contrast, BMD at the lumbar spine, femur neck, or total hip showed similar values between subjects with and without NAFLD.

The characteristics of subjects with NAFLD according to significant liver fibrosis status are described in Table 2. Levels of serum AST, ALT, triglycerides, and CAP were significantly higher in subjects with significant liver fibrosis than in those without significant fibrosis, while lumbar spine, femur neck, and total hip BMDs were markedly lower. The prevalence of overall osteopenia and osteoporosis in NAFLD patients with significant fibrosis was significantly higher than in those without significant fibrosis (P = 0.010). Fig 2 displays BMDs at lumbar spine, femur neck, and total hip among subjects with normal, NAFLD, and NAFLD with significant fibrosis. BMDs were similar between normal and NAFLD groups but, patients with NAFLD with significant fibrosis showed significant lower BMDs, compared to normal or NAFLD group (Ps<0.005).

Associations between BMD and metabolic measures

To assess the relationship between BMD and metabolic variables in patients with NAFLD, a univariate analysis was performed (Table 3). BMDs at all sites revealed strong inverse correlations with significant liver fibrosis (lumbar spine, r = –0.19, P = 0.032; femur neck, r = –0.19, P = 0.034; total hip BMD, r = –0.21, P = 0.016), while no significant association was found between liver steatosis and BMD.
Multivariate analysis

Among patients with NAFLD, multivariate linear regression analyses were performed to investigate the independent association between BMD and significant liver fibrosis (Table 4). After adjustment for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP (representing liver steatosis), significant liver fibrosis was independently associated with BMDs at the femur neck ($\beta = -0.18$, $P = 0.039$) and total hip ($\beta = -0.21$, $P = 0.005$) in patients with NAFLD.

Table 4. Characteristics of study participants.

| Variables                      | All (n = 231) | Subjects without NAFLD (n = 102, 44.2%) | Subjects with NAFLD (n = 129, 55.8%) | P value |
|--------------------------------|---------------|-----------------------------------------|--------------------------------------|---------|
| Age (years)                    | 61.8 ± 8.4    | 62.0 ± 8.8                               | 61.6 ± 8.0                           | 0.694   |
| Sex (women), n (%)             | 160 (69.3)    | 70 (68.6)                                | 90 (69.8)                            | 0.482   |
| BMI (kg/m²)                    | 24.5 ± 3.3    | 22.9 ± 3.0                               | 25.8 ± 3.1                           | <0.001  |
| Diabetes mellitus, n (%)       | 43 (18.6)     | 17 (16.7)                                | 26 (20.2)                            | 0.308   |
| Statin user, n (%)             | 72 (31.2)     | 24 (23.5)                                | 48 (37.2)                            | 0.018   |
| Osteopenia, n (%)              | 109 (47.2)    | 48 (47.1)                                | 61 (47.3)                            | 0.973   |
| Osteoporosis, n (%)            | 36 (15.6)     | 17 (16.7)                                | 19 (14.7)                            | 0.411   |
| Overall osteopenia and osteoporosis | 145 (62.8) | 65 (63.7)                                | 80 (62.0)                            | 0.891   |

Laboratory variables

| HbA1c (%)                      | 6.3 ± 1.0      | 6.1 ± 0.7                                | 6.5 ± 1.2                             | 0.019   |
| Fasting plasma glucose (mg/dL) | 103.2 ± 21.4   | 100.0 ± 18.7                             | 105.9 ± 23.2                          | 0.036   |
| AST (IU/L)                     | 33.6 ± 31.4    | 34.6 ± 40.4                              | 32.8 ± 21.9                           | 0.660   |
| ALT (IU/L)                     | 31.8 ± 28.9    | 26.7 ± 26.6                              | 35.7 ± 30.0                           | 0.018   |
| Calcium (mg/dL)                | 9.1 ± 0.5      | 9.1 ± 0.4                                | 9.1 ± 0.5                             | 0.606   |
| Albumin (mg/dL)                | 4.2 ± 0.4      | 4.1 ± 0.5                                | 4.2 ± 0.4                             | 0.020   |
| 25-hydroxy vitamin D (IU)      | 22.7 ± 10.9    | 22.6 ± 10.4                              | 23.0 ± 11.2                           | 0.830   |
| Total cholesterol (mg/dL)      | 174.8 ± 42.9   | 176.9 ± 49.3                             | 173.1 ± 37.2                          | 0.504   |
| TG (mg/dL)                     | 123.7 ± 69.8   | 105.8 ± 61.1                             | 136.6 ± 73.0                          | 0.001   |
| HDL cholesterol (mg/dL)        | 49.2 ± 14.4    | 52.7 ± 17.0                              | 46.5 ± 11.3                           | 0.002   |
| LDL cholesterol (mg/dL)        | 101.1 ± 32.3   | 103.9 ± 35.9                             | 98.9 ± 29.1                           | 0.278   |

DXA scan

| Lumbar spine BMD (g/cm²)       | 0.910 ± 0.174  | 0.896 ± 0.172                             | 0.921 ± 0.176                         | 0.280   |
| Lumbar spine T-score           | -0.87 ± 1.43   | -0.97 ± 1.37                              | -0.79 ± 1.48                          | 0.335   |
| Femur neck BMD (g/cm²)         | 0.693 ± 0.124  | 0.685 ± 0.120                             | 0.700 ± 0.128                         | 0.365   |
| Femur neck T-score             | -1.11 ± 1.05   | -1.19 ± 1.02                              | -1.05 ± 1.08                          | 0.322   |
| Total hip BMD (g/cm²)          | 0.838 ± 0.146  | 0.827 ± 0.139                             | 0.847 ± 0.151                         | 0.320   |
| Total hip T-score              | -0.35 ± 1.02   | -0.45 ± 0.97                              | -0.27 ± 1.07                          | 0.204   |

Transient elastography

| CAP (dB/m)                     | 262.9 ± 51.2   | 217.0 ± 24.0                              | 299.2 ± 35.3                          | <0.001  |
| IQR <SUP>CAP</SUP> (dB/m)      | 28.8 ± 13.0    | 30.7 ± 12.5                               | 27.3 ± 13.3                           | 0.056   |
| Liver stiffness value (kPa)    | 5.70 ± 4.15    | 5.62 ± 4.94                               | 5.76 ± 3.4                            | 0.810   |
| IQR <SUP>LS</SUP> (kPa)        | 0.73 ± 0.62    | 0.72 ± 0.70                               | 0.74 ± 0.55                           | 0.754   |
| IQR/median <SUP>LS</SUP>       | 0.13 ± 0.05    | 0.13 ± 0.05                               | 0.13 ± 0.06                           | 0.774   |
| Significant liver fibrosis (>7 kPa), n, % | 38 (16.5) | 10 (9.8)                                 | 28 (21.7)                             | 0.011   |

Values are presented as the mean ± standard deviation (SD) or n (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation parameter; DXA, dual-energy X-ray absorptiometry; HDL, high density lipoprotein; IQR, interquartile range; LDL, low density lipoprotein; NAFLD, nonalcoholic fatty liver disease; TG, triglycerides.

https://doi.org/10.1371/journal.pone.0182202.t001

Multivariate analysis

Among patients with NAFLD, multivariate linear regression analyses were performed to investigate the independent association between BMD and significant liver fibrosis (Table 4). After adjustment for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP (representing liver steatosis), significant liver fibrosis was independently associated with BMDs at the femur neck ($\beta = -0.18$, $P = 0.039$) and total hip ($\beta = -0.21$, $P = 0.005$) in patients with NAFLD.
Table 2. Comparison between subjects with and without significant liver fibrosis (LS >7 kPa) among subjects with NAFLD (n = 129).

|                                | Without significant fibrosis (LS value ≤7 kPa, n = 101) | With significant fibrosis (LS value >7 kPa, n = 28) | P value |
|--------------------------------|--------------------------------------------------------|---------------------------------------------------|---------|
| Age (years)                    | 61.9 ± 7.4                                              | 60.6 ± 10.1                                       | 0.775   |
| Sex (women), n (%)             | 67 (66.3)                                               | 23 (82.1)                                         | 0.081   |
| BMI (kg/m²)                    | 25.5 ± 3.0                                              | 26.6 ± 3.3                                        | 0.131   |
| Diabetes mellitus, n (%)       | 32 (16.6)                                               | 7 (25.0)                                          | 0.161   |
| Statin, n (%)                  | 41 (40.6)                                               | 7 (25.0)                                          | 0.097   |
| Osteopenia, n (%)              | 45 (44.6)                                               | 16 (57.1)                                         | 0.167   |
| Osteoporosis, n (%)            | 12 (11.9)                                               | 7 (25.0)                                          | 0.127   |
| Overall osteopenia and osteoporosis, n (%) | 57 (56.4)                                           | 23 (82.1)                                         | 0.010   |
| HbA₁c (%)                      | 6.4 ± 1.2                                               | 6.6 ± 1.2                                         | 0.253   |
| Fasting plasma glucose (mg/dL) | 106.5 ± 24.3                                            | 103.6 ± 18.5                                      | <0.001  |
| AST (IU/L)                     | 29.0 ± 18.1                                             | 46.3 ± 28.7                                       | <0.001  |
| ALT (IU/L)                     | 31.1 ± 27.1                                             | 52.5 ± 34.6                                       |         |
| Calcium (mg/dL)                | 9.0 ± 0.5                                               | 9.3 ± 0.5                                         | 0.011   |
| Albumin (mg/dL)                | 4.2 ± 0.3                                               | 4.4 ± 0.6                                         | 0.006   |
| 25-hydroxy vitamin D (IU)      | 22.6 ± 11.2                                             | 24.2 ± 11.3                                       | 0.527   |
| Total cholesterol (mg/dL)      | 174.0 ± 38.6                                            | 169.8 ± 32.1                                      | 0.491   |
| TG (mg/dL)                     | 129.3 ± 68.2                                            | 162.8 ± 84.2                                      | 0.022   |
| HDL cholesterol (mg/dL)        | 47.3 ± 11.9                                             | 43.7 ± 8.5                                        | 0.256   |
| LDL cholesterol (mg/dL)        | 98.9 ± 30.7                                             | 98.8 ± 22.7                                       | 0.997   |
| Lumbar spine BMD (g/cm²)       | 0.938 ± 0.180                                           | 0.858 ± 0.145                                     | 0.045   |
| Lumbar spine T-score           | -0.64 ± 1.51                                            | -1.32 ± 1.26                                      | 0.045   |
| Femur neck BMD (g/cm²)         | 0.712 ± 0.130                                           | 0.655 ± 0.111                                     | 0.048   |
| Femur neck T-score             | -0.96 ± 1.09                                            | -1.38 ± 1.00                                      | 0.100   |
| Total hip BMD (g/cm²)          | 0.864 ± 0.151                                           | 0.786 ± 0.137                                     | 0.023   |
| Total hip T-score              | -0.16 ± 1.04                                            | -0.69 ± 1.07                                      | 0.037   |
| CAP (dB/m)                     | 295.7 ± 34.0                                            | 312.0 ± 37.7                                      | 0.042   |
| Liver stiffness value (kPa)    | 4.65 ± 1.13                                             | 9.74 ± 5.43                                       | <0.001  |

Values are presented as the mean ± standard deviation (SD) or n (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation parameter; HDL, high density lipoprotein; LDL, low density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease; TG, triglycerides.

https://doi.org/10.1371/journal.pone.0182202.t002

Fig 2. Bone mineral density at lumbar spine, femur neck, and total hip among subject with normal, NAFLD, and NAFLD with significant fibrosis. NAFLD, non-alcoholic fatty liver disease.

https://doi.org/10.1371/journal.pone.0182202.g002
Multivariate logistic regression analyses were performed on significant liver fibrosis for overall osteopenia and osteoporosis in patients with NAFLD (Table 5). In the Model 1, the presence of significant liver fibrosis was associated with an increased risk for overall osteopenia and osteoporosis with an odds ratio of 3.55 (95% CI = 1.25–10.09). Subjects having NAFLD with significant fibrosis showed an independent association with overall osteopenia and osteoporosis (OR = 4.10, 95% CI = 1.02–16.45) in the model 5 adjusted for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP, compared to those having NAFLD without significant fibrosis.

Table 3. Factors associated with bone mineral density in subjects with NAFLD (n = 129).

| Variables                      | Lumbar spine (g/cm²) | Femur neck (g/cm²) | Total hip (g/cm²) |
|--------------------------------|----------------------|--------------------|-------------------|
|                                | r        | P value | r       | P value | r       | P value |
| Age (years)                    | 0.05     | 0.575   | -0.20   | 0.022   | -0.15   | 0.084   |
| Sex (male = 0, female = 1)     | -0.44    | <0.001  | -0.48   | <0.001  | -0.46   | <0.001  |
| BMI (kg/m²)                    | 0.21     | 0.019   | 0.31    | <0.001  | 0.31    | <0.001  |
| Diabetes mellitus              | 0.04     | 0.643   | 0.138   | 0.119   | 0.135   | 0.126   |
| HbA₁₀ (%)                      | 0.01     | 0.911   | 0.03    | 0.800   | 0.06    | 0.574   |
| Fasting blood glucose (mg/dL)  | 0.22     | 0.013   | 0.21    | 0.021   | 0.22    | 0.014   |
| AST (IU/L)                     | -0.24    | 0.006   | -0.07   | 0.421   | -0.09   | 0.306   |
| ALT (IU/L)                     | -0.19    | 0.029   | 0.01    | 0.903   | -0.01   | 0.977   |
| Calcium (mg/dL)                | -0.05    | 0.449   | 0.07    | 0.328   | 0.04    | 0.596   |
| Albumin (mg/dL)                | -0.16    | 0.068   | 0.03    | 0.760   | -0.05   | 0.586   |
| 25-hydroxy vitamin D (IU)      | -0.19    | 0.075   | -0.17   | 0.110   | -0.12   | 0.242   |
| Total cholesterol (mg/dL)      | -0.12    | 0.182   | -0.01   | 0.968   | -0.01   | 0.918   |
| TG (mg/dL)                     | -0.04    | 0.684   | 0.11    | 0.217   | 0.09    | 0.342   |
| HDL cholesterol (mg/dL)        | -0.22    | 0.015   | -0.19   | 0.046   | -0.15   | 0.104   |
| LDL cholesterol (mg/dL)        | -0.09    | 0.334   | -0.05   | 0.613   | -0.07   | 0.437   |
| CAP (dB/m)                     | -0.08    | 0.343   | 0.02    | 0.846   | 0.05    | 0.605   |
| Liver stiffness value (kPa)    | -0.03    | 0.745   | -0.06   | 0.469   | -0.07   | 0.457   |
| Signific ant liver fibrosis (LS > 7kPa) | -0.19    | 0.032   | -0.19   | 0.034   | -0.21   | 0.016   |

Log-transformed.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation parameter; HDL, high density lipoprotein; LDL, low density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease; TG, triglycerides.

Multivariate linear regression analysis of the correlation between BMD and significant liver fibrosis in subjects with NAFLD (n = 129).

Table 4. Multivariate linear regression analysis of the correlation between BMD and significant liver fibrosis in subjects with NAFLD (n = 129).

|                     | Lumbar spine BMD (g/cm²) | Femur neck BMD (g/cm²) | Total hip BMD (g/cm²) |
|---------------------|--------------------------|------------------------|-----------------------|
|                     | R²          | β         | P value | R²          | β         | P value | R²          | β         | P value |
| Model 1             | 0.028       | -0.19     | 0.032   | 0.027       | -0.19     | 0.034   | 0.037       | -0.21     | 0.016   |
| Model 2             | 0.214       | -0.15     | 0.064   | 0.308       | -0.17     | 0.025   | 0.288       | -0.21     | 0.007   |
| Model 3             | 0.230       | -0.12     | 0.163   | 0.344       | -0.18     | 0.020   | 0.332       | -0.23     | 0.003   |
| Model 4             | 0.189       | -0.10     | 0.312   | 0.320       | -0.20     | 0.028   | 0.369       | -0.23     | 0.013   |

Model 1: crude; Model 2: adjusted for age, sex, BMI; Model 3: adjusted for age, sex, BMI, fasting plasma glucose; Model 4: adjusted for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, CAP. ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation parameter; HDL, high density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease.
In the present study, we firstly applied liver TE (Fibroscan), a noninvasive tool for showing numerical values for liver steatosis based on CAP, and liver fibrosis based on LS, in order to investigate the association between liver fibrosis and osteopenia in patients with non-alcoholic fatty liver disease (NAFLD). We showed that BMD was reduced in subjects with significant liver fibrosis (LS > 7 kPa) and that the presence of significant liver fibrosis was correlated with low BMDs at all sites, including the lumbar spine, femur neck, and total hip in patients with NAFLD. After adjustment for all confounding variables, significant liver fibrosis remained an independent determinant of low BMD at the femur among NAFLD patients. Furthermore, subjects having NAFLD with significant fibrosis were significantly associated with overall osteopenia and osteoporosis compared to those having NAFLD without significant fibrosis.

Liver fibrosis is the result of a massive accumulation of extracellular matrix and scar formation, eventually resulting in cirrhosis [29]. Osteoporosis is a common complication of liver cirrhosis, which is a progressive and severe chronic liver disease, and up to about 40% of patients with chronic liver disease may be at risk of bone fracture [7,30]. Previously, children with NASH had a significantly lower BMD than those with NAFLD who did not have NASH [31]. In addition, as suggestive of NASH, subjects with NAFLD showing elevated serum ALT and C-reactive protein (CRP) were associated with low BMD [32]. Xia et al. reported that there was a synergistic worsening of the BMDs in subjects with both NAFLD and elevated serum ALT [33]. However, the relationship of liver fibrosis and BMD in asymptomatic subjects with NAFLD is poorly understood. In this study, the significant fibrosis in NAFLD, indicating progression of inflammation in liver steatosis, was markedly associated with low BMD. The association between NAFLD and osteopenia also remains controversial. NAFLD was associated with low lumbar BMD and osteoporotic fractures in children and adults in several studies [6,11,34]. Meanwhile, in men yet not in women, the presence of NAFLD was associated with osteoporotic fractures in another study [11], and simple steatosis of the liver did not affect BMD [32]. In this present study, the presence or absence of NAFLD did not significantly affect BMD values. However, the multivariate regression analysis revealed that significant liver fibrosis, not CAP, which indicated the degree of liver steatosis, was an independent determinant of low BMD. Therefore, we suggest that NAFLD subjects with significant liver fibrosis should be concerned about the risk of low BMD.

Interestingly, the presence of significant liver fibrosis remained an independent risk factor for low BMD only at the femur after adjustment of all confounding factors. In a crude model (model 1), the presence of significant liver fibrosis was an independent factor for spinal BMD;

### Table 5. Multivariate logistic regression analysis of significant liver fibrosis for overall osteopenia and osteoporosis in subjects with NAFLD (n = 129).

| Variables | OR   | 95% CI          | P value |
|-----------|------|-----------------|---------|
| Model 1   | 3.55 | 1.25–10.09      | 0.017   |
| Model 2   | 4.01 | 1.21–13.31      | 0.023   |
| Model 3   | 3.67 | 1.06–12.70      | 0.040   |
| Model 4   | 4.10 | 1.02–16.45      | 0.047   |

Model 1: crude; Model 2: adjusted for age, sex, BMI; Model 3: adjusted for age, sex, BMI, fasting plasma glucose; Model 4: adjusted for age, sex, BMI, fasting plasma glucose, ALT, HDL cholesterol, and CAP. ALT, alanine aminotransferase; BMD, bone mineral density; BMI, body mass index; CAP, controlled attenuation parameter; HDL, high density lipoprotein; LS, liver stiffness; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio.
however, it was not an independent factor after adjusting for confounding factors. We were unable to find an explanation for these discrepancies. However, in this context, previous studies showed that loss of BMD at the femur was greater than that at the lumbar spine in patients who underwent liver transplantation [35] as well as in those with alcoholic liver cirrhosis [36]. Compared to the controls, the thickness of the cortex was significantly thinner in patients with significant fibrosis, which might be explained by enhanced endocortical bone resorption [36].

Further study is required to explore the mechanism of preferential bone loss in cortical bone in patients with liver fibrosis.

The pathophysiology linking liver fibrosis to low bone mass has not been well established due to complex and multifactorial mechanisms. Pathogenic mediators, including fibronectin, IGF-1, the RANKL/OPG system, and several cytokines, such as TNF-α and the IL-6 family, have been suggested to play important roles in the pathogenesis of bone loss in chronic liver disease [30,37]. Lipotoxicity, reactive oxidative stress, activated hepatic macrophages releasing pro-inflammatory cytokines, and hepatocyte-derived extracellular vesicles released during lipotoxicity can modulate hepatic inflammatory/immune system leading to hepatic injury, NASH, and fibrosis [38,39]. In addition, hepatic inflammation and fibrosis are also linked to adipose inflammation and insulin resistance, through a release of inflammatory mediators such as TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1) from adipose tissue [40,41]. Therefore, our results showing a strong association between low BMD and significant liver fibrosis in NAFLD may be partly explained by the development of osteopenia through the systemic inflammation and insulin resistance observed in this disorder. Vitamin D deficiency may also contribute to worsening bone health in chronic liver disease [30,42]. Indeed, 92% of patients with chronic liver disease revealed vitamin D deficiency, although most had chronic hepatitis C [43]. Low vitamin D and high parathyroid hormone levels were independently associated with the presence of NAFLD [44]. In contrast, Goral et al. reported normal vitamin D levels in patients with liver cirrhosis [45], and no direct relationship between vitamin D levels and the severity of osteoporosis was detected [7,46]. Likewise, the current study demonstrated no significant difference in vitamin D levels according to the presence of significant liver fibrosis, and no significant correlation was found between BMD and the level of vitamin D. Taken together, more studies are required to elucidate the mechanism of liver fibrosis–associated bone loss.

The present study has several strengths. To our knowledge, this is the first study to investigate the association between BMD and liver fibrosis assessed via liver TE in patients with NAFLD. Therefore, we could measure liver fibrosis or steatosis using TE, and we were able to easily identify subjects who had liver steatosis and verify significant liver fibrosis without invasive investigation. Secondly, we excluded subjects with autoimmune hepatitis, chronic hepatitis B, chronic hepatitis C, alcoholic hepatitis, drug-induced hepatitis, primary biliary cirrhosis, right-sided heart failure, or a history of malignancy, which could have yielded LS values for fibrosis with a different distribution when assessed via TE [47,48].

The current study also has limitations. It was based on a cross-sectional study design, which made it difficult to determine a causal relationship between liver fibrosis and low BMD. Moreover, although liver TE has been used to assess fibrosis and steatosis, liver biopsies were not conducted in this study as a reference standard for diagnosis and assessment of the degree of fibrosis or steatosis. However, recent studies revealed that liver TE measurement is well correlated with the degree of fibrosis or steatosis assessed via biopsy [14,49]. There are also some issues that have to be taken into account when using TE. When interpreting results of TE, factors including obesity, presence of liver steatosis, and elevated levels of serum ALT may affect the results [50–52]. Also, as a substantial interoperator variability is presented, liver TE measurement made by the same operator with a high number of examinations for operator
experience may reduce the variation [53,54]. In the present study, liver TE was performed by a single experienced operator that may enhance the reliability of CAP and liver stiffness. Additionally, we did not assess bone turnover markers. Previous studies suggested that decreased bone formation or increased bone resorption affect the pathogenesis of hepatic osteodystrophy [7,10,55]. Moreover, factors may have a link with bone mineralization including use of hormonal replacement therapy, Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index in relation to insulin resistance, or CRP as a marker of systemic inflammation were not accessed in the study due to lack of these variables [56–58].

Conclusions

In conclusion, we confirmed that the presence of significant liver fibrosis assessed via liver TE (Fibroscan) was strongly associated with overall osteopenia and osteoporosis in asymptomatic individuals with NAFLD. Importantly, the presence of significant liver fibrosis was an independent determinant for low BMD in patients with NAFLD. Altogether, these finding indicated that the progression of hepatic inflammation and fibrosis might be closely related to bone loss. As advanced hepatic osteodystrophy is difficult to treat and could increase the burden on society with adverse long-term prognosis and increased morbidity, early screening and assessment for the risk of bone loss, even in asymptomatic NAFLD patients with significant liver fibrosis, must be considered. Furthermore, prospective studies are warranted to confirm the causative relationship between the presence of significant fibrosis and the development of bone loss.

Author Contributions

Conceptualization: GK SKL.
Data curation: GK KJK.
Formal analysis: GK.
Funding acquisition: SKL.
Investigation: GK KJK YR SKL.
Methodology: GK SKL.
Project administration: GK KJK YR SKL.
Resources: GK KJK YR SKL.
Software: GK.
Supervision: KJK YR SKL.
Validation: GK KJK YR SKL.
Visualization: GK.
Writing – original draft: GK.
Writing – review & editing: GK KJK YR SKL.

References

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of
Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55:205–23. https://doi.org/10.1002/hep.25762 PMID: 22488764

2. Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016; 15:249–74. https://doi.org/10.1038/nrd.2015.3 PMID: 26794269

3. Ekstedt M, Hagstrom H, Naar P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61:1547–54. https://doi.org/10.1002/hep.27368 PMID: 25250777

4. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011; 53:1874–82. https://doi.org/10.1002/hep.24268 PMID: 21360720

5. Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M. Hepatic osteodystrophy. Clin Cases Miner Bone Metab. 2014; 11:185–91. PMID: 25568651

6. Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine. 2012; 42:423–9. https://doi.org/10.1007/s12020-012-9639-6 PMID: 22407492

7. Yadav A, Carey EJ. Osteoporosis in chronic liver disease. Nutr Clin Pract. 2013; 28:52–64. https://doi.org/10.1177/0884533612470145 PMID: 23263929

8. Gioulême OI, Vyzantiadis TA, Nikolaidis NL, Vasiliadis TG, Papageorgiou AA, Eugenidis NP, et al. Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006; 53:938–43. PMID: 17153457

9. Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009; 6:660–70. https://doi.org/10.1038/nrgastro.2009.166 PMID: 19881518

10. Lupoli R, Di Minno A, Spadarella G, Ambrosino P, Panico A, Tarantino L, et al. The risk of osteoporosis in patients with liver cirrhosis: a meta-analysis of literature studies. Clin Endocrinol (Oxf). 2015 https://doi.org/10.1111.cen.12780 PMID: 25817369

11. Li M, Xu Y, Xu M, Ma L, Wang T, Liu Y, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab. 2012; 97:2033–8. https://doi.org/10.1210/jc.2011-3010 PMID: 22466338

12. Gallego-Roj o FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998; 28:695–9. https://doi.org/10.1002/hep.510280315 PMID: 9731561

13. Kim SY. Noninvasive markers for the diagnosis of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 2013; 28:280–2. https://doi.org/10.3803/EnM.2013.28.4.280 PMID: 24396692

14. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultras Med Biol. 2003; 29:1705–13. PMID: 14698338

15. de Ledinghen V, Vergioli J, Capdepon M, Chermark F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014; 60:1026–31. https://doi.org/10.1016/j.jhep.2013.12.018 PMID: 24378529

16. Seo YS, Kim MY, Kim SJ, Hyun BS, Jiang JY, Lee JW, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int. 2015 https://doi.org/10.1111/liv.12808 PMID: 25682719

17. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007; 5:1214–20. https://doi.org/10.1016/j.cgh.2007.07.020 PMID: 17916549

18. de Ledinghen V, Vergioli J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012; 32:911–8. https://doi.org/10.1111/j.1478-3231.2012.02820.x PMID: 22672642

19. Kim W, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The glycate albumin to glycated hemoglobin ratio might not be associated with carotid atherosclerosis in patients with type 1 diabetes. Diabetes Metab J. 2014; 38:456–63. https://doi.org/10.4093/dmj.2014.38.6.456 PMID: 25541609

20. Fukuyama N, Homma K, Wakana N, Kudo K, Suyama A, Ohazama H, et al. Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. J Clin Biochem Nutr. 2008; 43:1–5. https://doi.org/10.3164/jcbn.2008-036 PMID: 18648653

21. Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, Miller PD, et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res. 2005; 20:195–201. https://doi.org/10.1359/jbmr.041115 PMID: 15647812
22. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008; 42:467–75. https://doi.org/10.1016/j.bone.2007.11.001 PMID: 18180210

23. Kim SU, Ahn SH, Park JY, Kang W, Kim do Y, Park YN, et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol. 2009; 43:267–71. https://doi.org/10.1097/MCG.0b013e31816f212e PMID: 18987556

24. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012; 36:13–20. https://doi.org/10.1016/j.clinre.2011.08.001 PMID: 21920839

25. Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014; 34:102–9. https://doi.org/10.1111/liv.12282 PMID: 24028214

26. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. J Gastroenterol Hepatol. 2015; 30:1536–42. https://doi.org/10.1111/jgh.12992 PMID: 25973647

27. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015; 21:1158–66. https://doi.org/10.3748/wjg.v21.i4.1158 PMID: 25632188

28. Kim BK, Kim SU, Choi GH, Han WK, Park MS, Kim EH, et al. "Normal" liver stiffness values differ between men and women: a prospective study for healthy living liver and kidney donors in a native Korean population. J Gastroenterol Hepatol. 2012; 27:781–8. https://doi.org/10.1111/j.1440-1746.2011.06962.x PMID: 22098121

29. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011; 6:425–56. https://doi.org/10.1146/annurev-pathol-011110-130246 PMID: 21073339

30. Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World J Gastroenterol. 2014; 20:9427–38. https://doi.org/10.3748/wjg.v20.i28.9427 PMID: 25071337

31. Pardee PE, Dunn W, Schwimmer JB. Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther. 2012; 35:248–54. https://doi.org/10.1111/j.1365-2036.2011.04924.x PMID: 22111971

32. Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M. The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr. 2012; 124:526–31. https://doi.org/10.1007/s00508-012-0211-4 PMID: 22850810

33. Xia MF, Lin HD, Yan HM, Bian H, Chang XX, Zhang LS, et al. The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women. J Transl Med. 2016; 14:11. https://doi.org/10.1186/s12967-016-0766-3 PMID: 26791408

34. Tarhger G, Lonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest. 2015; 38:817–25. https://doi.org/10.1007/s40618-015-0315-6 PMID: 26003827

35. Keogh JB, Tsalamanidris C, Sewell RB, Jones RM, Angus PW, Nyulasi IB, et al. Bone loss at the proximal femur and reduced lean mass following liver transplantation: a longitudinal study. Nutrition. 1999; 15:661–4. PMID: 10467609

36. Culafic D, Djonic D, Culafic-Vojinovic V, Ignjatovic S, Soldatovic I, Vasic J, et al. Evidence of degraded BMD and geometry at the proximal femora in male patients with alcoholic liver cirrhosis. Osteoporos Int. 2015; 26:253–9. https://doi.org/10.1007/s00198-014-2849-4 PMID: 25172381

37. Gaudio A, Lasco A, Morabito N, Atteritano M, Vergara C, Catalano A, et al. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? J Endocrinol Invest. 2005; 28:677–82. PMID: 16277162

38. Bertola A, Bonafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 2010; 5:e13577. https://doi.org/10.1371/journal.pone.0013577 PMID: 21042596

39. Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J. 2016; 40:1–11. https://doi.org/10.4093/dmj.2016.40.1.1 PMID: 26812150

40. Clement S, Juge-Aubry C, Sgroi A, Conzelmann S, Pazienza V, Pittet-Cuenod B, et al. Monocyte chemotactrant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology. 2008; 48:799–807. https://doi.org/10.1002/hep.22404 PMID: 18570214
41. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010; 25:672–90. https://doi.org/10.1111/j.1440-1746.2010.06253.x PMID: 20492324

42. Hajiabasi A, Shafaghi A, Fayazi HS, Shenavar Masooleh I, Hedayati Emami MH, Ghavidel Parsa P, et al. The factors affecting bone density in cirrhosis. Hepat Mon. 2015; 15:e26871. https://doi.org/10.5812/hepatomon.15(2).26871 PMID: 25977695

43. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010; 55:2624–8. https://doi.org/10.1007/s10620-009-1069-9 PMID: 19960254

44. Bhatt SP, Nigam P, Misra A, Guleria R, Qadar Pasha MA. Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India. Atherosclerosis. 2013; 230:157–63. https://doi.org/10.1016/j.atherosclerosis.2013.07.006 PMID: 23958268

45. Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol. 2010; 16:1639–43. https://doi.org/10.3748/wjg.v16.i13.1639 PMID: 20355242

46. Chang EJ, Yi DY, Yang HR. Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease. J Korean Med Sci. 2015; 30:1821–7. https://doi.org/10.3346/jkms.2015.30.12.1821 PMID: 26713058

47. Friederich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut. 2008; 57:1288–93. https://doi.org/10.1037/gastro.2008.01.034 PMID: 18395077

48. Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim do Y, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014; 34:102–9. https://doi.org/10.1111/liv.12282 PMID: 24028214

49. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66:1022–30. https://doi.org/10.1016/j.jhep.2016.12.022 PMID: 28039099

50. Nascimbeni F, Lebray P, Fedchuk L, Oliveira CP, Alvares-da-Silva MR, Varault A, et al. Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. Clin Gastroenterol Hepatol. 2015; 13:763–71.e1–6. https://doi.org/10.1016/j.cgh.2014.07.037 PMID: 25086193

51. Perazzo H, Fernando FF, Gomes A, Terra C, Perez RM, Figueiredo FA. Interobserver variability in transient elastography analysis of patients with chronic hepatitis C. Liver Int. 2015; 35:1533–9. https://doi.org/10.1111/liv.12551 PMID: 24684234

52. Pirgon O, Bilgin H, Tolu I, Odabas D. Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2011; 75:189–95. https://doi.org/10.1111/j.1365-2265.2011.04038.x PMID: 21521307